Intravenous immune globulin in the treatment of intractable childhood epilepsy

Clinical and Experimental Immunology, Supplement

Volumn 104, Issue SUPPL. 1, 1996, Pages 71-76

  Duse, M ^a   Notarangelo, L D ^a   Tiberti, S ^b   Menegati, E ^b   Plebani, A ^a   Ugazio, A G ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Children's Hospital   (Italy)

Author keywords

Intractable childhood epilepsy; Intravenous immune globulin

Indexed keywords

IMMUNOGLOBULIN;

CHILD; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EPILEPSY; HUMAN; INTRACTABLE EPILEPSY; INTRAVENOUS DRUG ADMINISTRATION; LENNOX GASTAUT SYNDROME; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WEST SYNDROME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CONTROLLED CLINICAL TRIALS; DOUBLE-BLIND METHOD; EPILEPSY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; RECURRENCE;

EID: 0030000701     PISSN: 09642536     EISSN: None     Source Type: Journal    
DOI: 10.1111/cei.1996.104.s1.71     Document Type: Article

References (68)

1. Aicardi J. Diagnosis and differential diagnosis. In: Epilepsy in children. New York: Raven Press, 1986: pp. 287-308.
2. Livingston JH. Management of intractable epilepsy. Arch Dis Child 1991; 66:1454-6.
3. Aarli JA, Fontana A. Immunological aspects of epilepsy. Epilepsia 1980; 21:451-7.
4. Leickly FE, Buckley RH. Development of IgA and IgG2 subclass deficiency after sulfasalazine therapy. J Pediatr 1986; 108:481-2.
5. Iivanainen M, Syrjanen J, Waltimo O et al. Bacterial antibody levels and IgA deficiency in epileptic patients. Br Med J 1987; 294:677.
6. Aicardi J, Chevrie JJ. Accidents neurologiques consecutifs à la vaccination contre la coquèluche. Arch Fr Pediatr 1975; 32:309-17.
7. Johnson RT, Griffin DE, Hirsch RL et al. Measles encephalomyelitic studies. N Engl J Med 1984; 310:137-41.
8. Hemachuda T, Griffin DE, Giffels J et al. Myelin basic protein as an encephalitogen in encephalomyelitis and polyneuritis following rabies vaccination. N Engl J Med 1987; 316:369-74.
9. Bowen FP, Kosarova J, Casella D et al. Focal epileptogenic activity induced by topical application of antisera to brain actomyosin-like protein. Brain Res 1976; 102:363-7.
10. Karpiak SE, Graf L, Rapport MH. Antiserum to brain gangliosides produces recurrent epileptic-form activity. Science 1976; 194:735-7.
11. Mihailovic LJ, Cupic D. Epileptiform activity evoked by intracerebral injection of anti-brain antibodies. Brain Res 1971; 32:97-124.
12. Walker A. Allergic phenomena as basic mechanism in epilepsy. In: Jasper HH, Ward AA, Pope A, eds. Basic Mechanisms of the Epilepsies. London: Churchill, 1969:812-9.
13. Rogers SW, Andrews PI, Gahring LC et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 1994; 265:648-51.
14. Twyman RE, Gahring LC, Spiess J, Rogers SW. Glutamate receptor antibodies activate a subset of receptors and reveal an agonist binding site. Neuron 1995; 14:755-62.
15. Pechadre JC, Sauvezie B, Osier C, Gibert J. Treatment des encephalopathies epileptiques de l'enfants par les gammaglobulines (results preliminaires). Rev EEG Neurophys Clin 1977; 7:443-7.
16. Laffont F, Esnault S, Gilber A et al. Effects des gammaglobulines sur les epilepsies rebelles. Etude preliminaire. Ann Med Interne (Paris) 1979; 130:307-12.
17. De Feo MR, Formica MM, Rocchi L. Effetti delle gammaglobuline sulla frequenza delle crisi e sulle alterazioni dell'EEG di bambini con epilessia. Riv Ital EEG Neurofisiol Clin 1981; 1(Suppl 1):65-6.
18. Bedini R, De Feo MR, Orano A, Rocchi L. Effect of gammaglobulin therapy in severely epileptic children. Epilepsia 1985; 26:98-102.
19. Ariizumi M, Baba K, Shiihara H et al. High dose gammaglobulin for intractable childhood epilepsy (Letter). Lancet 1983; ii:162-3.
20. Ariizumi M, Baba K, Hibio S et al. Immunoglobulin therapy in the West syndrome. Brain Dev 1987; 9:422-5.
21. Sandsted P, Kostulas V, Larsson LE. Intravenous gammaglobulin for postencephalitic epilepsy. Lancet 1984; ii:1154-5.
22. Duse M, Tiberti S, Plebani A et al. IgG2 deficiency and intractable epilepsy of childhood. Monogr Allergy 1986; 20:128-34.
23. Duse M, Tiberti S, Menegati E et al. Intractable childhood epilepsy and IgG2 deficiency: evidence for a dose dependent therapeutic effect of intravenous gammaglobulin. In: Vossen J, Griscelli C, eds. Progress in Immunodeficiency Research and Therapy II. Amsterdam: Elsevier, 1986:205-9.
24. Plebani A, Duse M, Tiberti S et al. Intravenous gammaglobulin therapy and serum IgG subclass levels in intractable childhood epilepsy. Monogr Allergy 1988; 23:204-15.
25. Ugazio AG, Duse M, Menegati E et al. Intravenous immunoglobulin in the treatment of recurrent seizures. In: Eibl M, ed. Symposium in Immunology III. Neusatz: Springer-Verlag, 1994;197-204.
26. Sterio M, Gebauer E, Vicicevic G et al. Intravenoses Immunoglobuiin bei der Behandlung von malignen Epilepsien bei Kindern. Wien Klin Wochenschr 1990; 102:230-3.
27. Sterio M, Gebauer E, Zalisevslcij G et al. Treatment of malignant epilepsies in children with intravenous immunoglobulin. Poster presented at the 18th Annual Meeting of the Society of Neuropediatrics, 1989; Vienna, Austria.
28. Heilmann C, Tandorf K, Illum N et al. Treatment of Lennox Gastaut's epilepsy with IVIG. Proceedings of the Meeting of European Group for Immunodeficiencies. Viterbo, Sept. 11-13, 1988:122 (Abstract).
29. Echenne B, Parayre-Chanez MJ, Clot J, Baly-Moulinier M. Treatment of infantile spasms with intravenous gammaglobulins. Neuropediatrics 1987; 18:126.
30. Echenne B, Dulac O, Parayre-Chanez MJ et al. Treatment of infantile spasms with intravenous gamma-globulins. Brain Dev 1991; 13:313-19.
31. Ariizumi M, Hibio S, Ogawa K et al. Comparative study on nontreated and pepsin treated immunoglobulin therapy for idiopathic Lennox syndrome. Brain Dev 1984; 4:422-3.
32. Shiihara H, Michihiro N, Ogawa K et al. Gamma-globulin therapy in infantile spasms. Brain Dev 1984; 6:198.
33. Hibio S, Mikihirio N, Ogawa K et al. Clinical effects and serum immunoglobulin changes following non-treated immunoglobulin administration in West syndrome. Brain Dev 1985; 7:183.
34. Von Rijckevorsel-Harmant K, Delire M, Rucquoy-Ponsar M. Treatment of idiopathic West and Lennox-Gastaut syndromes by IV administration of human polyvalent Ig. Eur Arch Neurol Sci 1986; 236:119-22.
35. Dalla Bernardina BD, Andrighetto G, Fontana E et al. Intravenous gammaglobulin in early childhood intractable epilepsies. XII Epilepsy Int. Cong. Jerusalem: 1987; 29 (Abstract).
36. Buti D, Lini M, Romano G et al. Studio sull'efficacia della somministrazione di gammaglobuline endovena in 10 bambini con epilessia intrattabile. Acta Pediatrica Latina 1988; 41:171-3.
37. Balestri P, Fois A, Tomaccini D et al. L'epilessia intrattabile. Acta Pediatrica Latina 1988; 41:466-71.
38. Spina A, Losito R, Marzocco P, Damato R. Treatment of intractable childhood epilepsy with high doses of intravenous gammaglobulins. Acta Neurol 1989; 11:415-22.
39. Schwartz SA, Gordon KE, Johnston MV, Goldstein GW. Use of intravenous immune globulin in the treatment of seizure disorders. J Allergy Clin Immunol 1989; 84:603-7.
40. Fois A, Vascotto M. Use of intravenous immunoglobulin in drug-resistant epilepsy. Child's Nerv Syst 1990; 6:400-5.
41. Etzioni A, Jaffe M, Pollack S et al. High dose intravenous gamma-globulin in intractable epilepsy of childhood. Eur J Pediatr 1991; 150:681-3.
42. Van Engelen BGM, Strengers BFW, Renier WO, Weemaes CMR. Study of immunological aspects of therapy resistant childhood epilepsy. Effects of therapy with Intravenous Immunoglobulin. In: Imbach P, ed. Immunotherapy with intravenous immunoglobulins. London: Academic Press, 1991:467-8.
43. Gross-Tsur V, Shalev RS, Kazir E et al. Intravenous high dose gammaglobulins for intractable childhood epilepsy. Acta Neurol Scand 1993; 88:204-9.
44. Connolly MB, Jan JE, Junker AK. Intravenous immunoglobulin and pyridoxine-dependent seizures (Letter). Neurology 1991; 41:1524.
45. Van Engelen BGM, Renier WO, Weemaes CMR et al. High dose intravenous immunoglobulin treatment in cryptogenic West and Lennox-Gastaut syndrome; an add-on study. Eur J Pediatr 1994; 153:762-9.
46. Hara M, Fukuyama Y. Therapeutic trial for intractable epilepsy of infusion of massive doses of gammaglobulin in children. Brain Dev 1985; 7:76-7.
47. Reitter B, Walther B, Schmitt T. BNSanfaelle: behandung mit 7-S-immunoglobulin G. In: Fichsel H, ed. Aktuelle Neuropaediatriae. Berlin: Springer, 1986:291-5.
48. Baetz-Greenwalt B, Rothner AD, Saracusa C et al. Lack of benefit of intravenous gammaglobulin in the treatment of intractable childhood epilepsy in children with and without IgG subclass deficiency (Abstract). Ann Neurol 1992; 32:434.
49. Van Engelen BGM, Renier WO, Weemars CMR et al. Immunoglobulin treatment, a review of the literature. Epilepsy Research 1994; 19:181-90.
50. Illum N, Taudorf K, Heilmann C et al. Intravenous immunoglobulin: a single-blind trial in children with Lennox-Gastaut syndrome. Neuropediatrics 1990; 21:87-90.
51. Van Rijckevorsel-Harmant K, Delire M, Schmitz-Moorman W, Wieser HG. Treatment of refractory epilepsy with intravenous immunoglobulins. Results of the first double-blind/dose finding clinical study. Int J Clin Lab Res 1994; 24:162-6.
52. Ugazio AG, Duse M, Plebani A et al. Intravenous immunoglobulin: prevention and treatment of disease. NIH Consensus Development Conference. 1990;147-50.
53. Daute KH, Hassel A, Klust E. Mioklonish - astatische Petit mal: immunologische Aspekte in Aetiopathogenefe und Therapie. In: IVth Prague International Symposium of child neurology. Berlin, Heidelberg, New York: Springer, 1978;16.
54. Hirayama H, Kurimoto T, Wada S et al. Anti-epileptic effects of globulin N, an intact human immunoglobulin and its tissue distribution in kindled cats. Int J Clin Pharmacol Ther Toxicol 1986; 24:109-22.
55. Fateh-Moghadam A, Wick M, Besinger U, Guersen RG. High-dose intravenous gammaglobulin for myasthenia gravis (letter). Lancet 1984 ii:848-9.
56. Eibl MM, Wedgwood RJ. Intravenous immunoglobulin: a review. Immunodefic Rev 1989; 1(Suppl):1-42.
57. Evans MJ, Suenaga R, Abdou NI. Detection and purification of antiidiotypic antibody against anti-DNA in intravenous gammaglobulin. J Clin Immunol 1991; 11:291-5.
58. Stohl W. Cellular mechanisms in the in vitro inhibition of pokeweed mitogen-induced B cell differentiation by immunoglobulin for intravenous use. J Immunol 1986; 136:4407-13.
59. Chander R, Papadopoulos S, Schiff RI. Suppression of cellular immune response by intravenous gammaglobulin (IVIG). J Allergy Clin Immunol 1990; 85:220A.
60. Vassilev T, Gelin C, Kaveri SV et al. Antibodies to CD5 molecule in normal immunoglobulins for therapeutic use. Clin Exp Immunol 1993; 92:369-72.
61. Marchalonis JJ, Daymaz U, Dedeoglu R et al. Human autoantibodies reactive with synthetic autoantigens from T cell receptor β chain. Proc Natl Acad Sci USA 1992; 89:3325-9.
62. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992; 326:107-16.
63. Berchtold P, McMillan R. Intravenous immunoglobulin: new aspects of mechanism of action in chronic ITP. In: Imbach P, ed. Immunotherapy with Intravenous Immunoglobulins. London: Academic Press, 1991:245-52.
64. Gilhus NE, Lea T. IgG subclasses in epileptic patients treated with phenytoin. J Neurol 1989; 236:149-52.
65. Gilhus NE, Lea T. Carbamazepine: effect on IgG subclasses in epileptic patients. Epilepsia 1988; 28:317-20.
66. Ishizaka A, Nakanishi M, Kasahara E et al. Phenytoin-induced IgG2 and IgG4 deficiencies in a patient with epilepsy. Acta Paediatr 1992; 81:646-8.
67. Ugazio AG, Duse M, Plebani A et al. Il Bambino Immunodepresso: Perchè to e e Come Va Difeso. Edizione. CEA, Milano, 1995: pp. 205-6.
68. Iannetti P, Fiorilli M, Sirianni MC et al. Nonfebrile seizures after febrile convulsions: possible role of chronic cytomegalovirus infection. J Pediatr 1982; 101:27-31.